The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
OLI Premium
IPOs
Secondary Offerings
Private Placements
Corporate Bonds
Top 20 Large Caps
Top 20 Biggest ETFs
Earnings Calendar
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Weekly Market Wrap
Articles
Dunnan On Dollars
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., May. 21, 3:22 PM

This Slide: #11 of 25

Slide #11. Stemline Therapeutics, Inc. — Secondary Offering

Company: Stemline Therapeutics, Inc. (NASDAQ:STML)
Shares Offered: 4,137,931
Date of Pricing: 5/16/2013
Price Per Share: $14.50
Secondary Offering Details: Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $14.50 per share. Stemline has granted the underwriters a 30-day option to purchase up to 620,689 additional shares of common stock from Stemline. The gross proceeds to Stemline from the public offering are expected to be $60.0 million, before underwriting discounts and commissions and other estimated offering expenses. Stemline intends to use the net proceeds from the public offering to fund the clinical development of SL-401 and SL-701 and other general corporate purposes.

Stemline Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk. Among the therapeutic candidates in Co.'s portfolio, Co. is developing two clinical-stage product candidates, SL-401 and SL-701, for which Co. holds global marketing rights. The indications for SL-401, a biologic targeted therapy, are blastic plasmacytoid dendritic cell neoplasm, a rare hematologic cancer, and acute myeloid leukemia. The indications for SL-701, a therapeutic cancer vaccine comprised of synthetic peptides, are pediatric and adult brain cancer.
Open the STML Page at The Online Investor »

STML — Key Stats (updated 4 hours, 22 minutes ago)
Company Name:  Stemline Therapeutics Inc
Website:  www.stemline.com
Sector:  Drugs & Pharmaceuticals
 

Open the STML Page at The Online Investor (in a new window) »
May 21, 2013  •  3:22 PM Eastern
STML — Current Quote
Quotes delayed 20 minutes

Trade STML Now:

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2013, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.